Genome Editing for a Better Life




Drug Target HTS
High-throughput screening based on CRISPR technology. The platform can carry out pharmaceutical research, such as drug research, Drug target screening, synthetic lethal screening, drug resistance gene screening, drug sensitive gene screening and gene function analysis.
Our service includes:
1. Coding gene screening
2. Paired gRNA LncRNA screening
3. Single sgRNA LncRNA screening

EdiGo Bioinformatics for pharmaceuticals
EdiGo Bioinformatics platform is built up on EdiGene‘s proprietary technology, and utilized to further research and treatment for our clients in the broad field of genome analysis, gene therapy, and gene editing. EdiGo allows for the development and design of sgRNA with high efficiency and specificity. We leverage the designed sgRNA for genome editing of targeting cells and offer our clients high-throughput screening services based on our unique genome editing techniques. By using EdiGo Bioinformatics platform to analyze the sequencing information of drug-treated edited cells, can finally obtain the target information related to such drug, which will be used in future clinical development and patient screening.

CRISTMAS Pharmaceutical research services
Parseqmus Pharmaceutical research services

Precise identification of functional elements for a potential lead compound/drug target is pretty important for achieving a lead compound/drug mechanistic understanding and the personalized, precision medicine. CRISPR-empowered Tiling Mutagenesis combined with Assorted-DNA-fragment Sequencing (CRISTMAS) provides a streamlined workflow and bioinformatics analytics for identifying critical elements of proteins in their native biological contexts at the single amino acid level.
Our service includes:
1. Research and Explore the truly functional amino acids for a potential lead compound/drug target.
2. Research and Explore the specifically functional region for a potential lead compound/drug target.

iBAR technology for Pharmaceutical research
Target-identification and mechanism-of-action studies have important roles in drug discovery. The iBAR screens outperforms the conventional method by producing screening results with much lower false-positive and false-negative rates especially with a high multiplicity of infection (MOI). Importantly, the iBAR approach reduces the starting cells at high MOI significantly with greatly improved efficiency and accuracy compared with the canonical CRISPR screens at a low MOI.
Our service includes:
Explore the functional targets for a potential lead compound/drug target with reduced workload.

Leave us a message





Click to follow us